PARP inhibitors: enhancing efficacy through rational combinations.

Bhamidipati, Deepak; Haro-Silerio, Jaime I; Yap, Timothy A; Ngoi, Natalie

Bhamidipati, Deepak; Haro-Silerio, Jaime I; Yap, Timothy A; Ngoi, Natalie.

Afiliação

Bhamidipati D; Department of Cancer Medicine Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Haro-Silerio JI; Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA.
Yap TA; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.
Ngoi N; The Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.

Br J Cancer ; 129(6): 904-916, 2023 10.

Article em En | MEDLINE | ID: mdl-37430137

Assuntos

Neoplasias; Inibidores de Poli(ADP-Ribose) Polimerases; Feminino; Humanos; Genes BRCA2; Neoplasias/tratamento farmacológico; Neoplasias/genética; Neoplasias Ovarianas/genética; Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia; Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Poli(ADP-Ribose) Polimerases / Neoplasias Limite: Female / Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google